We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-1.67%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$954M
AUM Growth
-$71.4M
Cap. Flow
-$2.48M
Cap. Flow %
-0.26%
Top 10 Hldgs %
46.58%
Holding
81
New
11
Increased
16
Reduced
19
Closed
9

Top Buys

1
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$20.6M
2
THOR
THORATEC CORPORATION
THOR
+$14.2M
3
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$13.8M
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$11.5M
5
KND
Kindred Healthcare
KND
+$10.8M

Top Sells

1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$19.4M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$15.5M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$14.7M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$13.5M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$9.6M

Sector Composition

1 Healthcare 78.52%
2 Consumer Discretionary 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
1
DELISTED
Avadel Pharmaceuticals
AVDL
$71.6M 7.51%
5,005,613
-262,298
-5% -$3.77M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$62.5M 6.55%
5,088,883
+735,669
+17% +$8.55M
AMAG
3
DELISTED
AMAG Pharmaceuticals
AMAG
$48.2M 5.05%
1,510,775
-450,000
-23% -$9.6M
PGNX
4
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$46.5M 4.87%
8,951,169
+2,315,000
+35% +$11.5M
EBS icon
5
Emergent Biosolutions
EBS
$394M
$44.3M 4.65%
2,080,519
– –
ANGO icon
6
AngioDynamics
ANGO
$558M
$40.8M 4.28%
2,975,227
+4,717
+0.2% +$67.3K
ASRT
7
DELISTED
Assertio
ASRT
$35.1M 3.68%
38,562
-2,633
-6% -$2.11M
BDSI
8
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$34.7M 3.64%
2,032,435
-1,339,619
-40% -$19.4M
AEGR
9
DELISTED
Aegerion Pharmaceuticals
AEGR
$33.6M 3.52%
1,006,562
+196,518
+24% +$6.1M
PTX
10
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$26.9M 2.82%
350,000
– –
HRTX icon
11
Heron Therapeutics
HRTX
$89.1M
$23.4M 2.45%
2,808,173
– –
AMPH icon
12
Amphastar Pharmaceuticals
AMPH
$871M
$23M 2.42%
+1,977,854
New +$20.6M
TVTX icon
13
Travere Therapeutics
TVTX
$5.27B
$22.9M 2.4%
2,558,854
+883,603
+53% +$10.4M
TTPH
14
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$19.1M 2.01%
47,962
-57,825
-55% -$15.5M
ANAC
15
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$19.1M 2%
780,820
-662,400
-46% -$13.5M
IPXL
16
DELISTED
Impax Laboratories, Inc.
IPXL
$15.6M 1.64%
658,929
+50,000
+8% +$1.28M
DSCI
17
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$15.2M 1.59%
1,824,377
– –
UAM
18
DELISTED
Universal American Corp
UAM
$15.1M 1.59%
1,880,359
-606,100
-24% -$5.01M
WINT
19
DELISTED
Windtree Therapeutics Inc
WINT
$14.8M 1.56%
576,143
– –
PETX
20
DELISTED
Aratana Therapeutics, Inc.
PETX
$14.5M 1.52%
1,442,435
+625,000
+76% +$7.58M
NTUS
21
DELISTED
Natus Medical Inc
NTUS
$13.7M 1.44%
464,915
-300,000
-39% -$8.28M
ATRC icon
22
AtriCure
ATRC
$1.77B
$13.6M 1.43%
925,902
-59,291
-6% -$944K
THOR
23
DELISTED
THORATEC CORPORATION
THOR
$13.4M 1.4%
+500,000
New +$14.2M
RIGL icon
24
Rigel Pharmaceuticals
RIGL
$750M
$11.6M 1.22%
599,802
+40,000
+7% +$1.13M
INFI
25
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$11.5M 1.2%
854,384
-584,100
-41% -$6.96M
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Broadfin Capital held 81 positions worth $954M, down 7% from $1.03B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Broadfin Capital's Q3 2014 filing shows 11 new, 16 increased, 19 reduced and 9 closed positions. Its largest new stake was Amphastar Pharmaceuticals: 1,977,854 shares worth $23M. The largest sale was BioDelivery Sciences International, Inc., an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Consumer Discretionary.

  • Broadfin Capital's largest Q3 2014 buy was Amphastar Pharmaceuticals: 1,977,854 shares worth $23M.
  • Broadfin Capital added most to Progenics Pharmaceuticals Inc in Q3 2014, an estimated $11.5M increase.
  • Broadfin Capital's biggest Q3 2014 reduction was BioDelivery Sciences International, Inc., cutting an estimated $19.4M.
  • Broadfin Capital fully exited Option Care Health in Q3 2014, selling an estimated $9.58M.
  • Broadfin Capital's ten largest holdings make up 47% of its $954M portfolio in Q3 2014.
  • Broadfin Capital opened 11 new positions and closed 9 in Q3 2014.
  • Broadfin Capital's portfolio value fell 7% quarter-over-quarter to $954M.

Based on Broadfin Capital's 13F filing for Q3 2014, filed 14 Nov 2014.